Biocept (BIOC) Misses Q2 EPS by 14c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/11/2026
- S&P 500, Dow futures attempt recovery ahead of inflation report
- Oracle raises full year profit guidance, stock rises after hours
- Oil surges 6%, Brent and US crude both surpass $100 on more tanker attacks
- Analysts split on Apple after foldable iPhone Duo debut
- JPMorgan upgrades Meta on AI models and agents, sees 'meaningful headroom'
- White House copper tariff plan stalls amid affordability concerns, sources say
- Micron's Taiwan workers to get rewards worth up to 68 months of pay
- Crude Inventory 0.4M Barrels Last Week - EIA
- Vertiv shares drop on acquisition skepticism, AI pullback
- S&P 500, Dow futures attempt recovery ahead of inflation report
- After-Hours Movers: ORCL, CRWV, ADBE, ACVA, CPRT, ZUMZ, PMTS, RH
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
Biocept Reports Second Quarter 2021 Financial Results
August 16, 2021 4:05 PM EDTSecond quarter revenues of $12.0 million driven by RT-PCR COVID-19 testing Continued sequential-quarter CNSide volume growth with customer base expanding to more than 30 leading U.S. academic institutions, including multiple repeat users Issued coverage with high-value payment by Medicare for the Target Selector breast cancer assay to detect the HER2 biomarker Received nearly 500,000 samples for COVID-19 RT-PCR testing since June 2020
Conference call begins at 4:30 p.m. Eastern time today
SAN DIEGO--(BUSINESS... More
